Sunday

Effect of Amprya (Fampridine-PR (prolonged released 4-aminopyridine)) on the manual functions of patients with MS: STUDY































Image Source: HEALTH

Effect of Ampyra (Fampridine-PR / prolonged released 4-aminopyridine) on the manual functions of patients with MS: STUDY
















Image Source: DRUGS.COM

MS Patients Show Better Gait and Balance with Ampyra (Dalfampridine) Treatment


























Withdrawal/reinitiation study expands on known walking speed benefits of approved MS therapy

In a new study, researchers evaluated the effect of dalfampridine treatment in people with multiple sclerosis (MS) and observed significant improvements in not only walking speed and distance, but also in gait and balance. The paper, titled “Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis,” was published in the International Journal of MS Care.

Safety profile of Ampyra (dalfampridine) extended release in MSs: 5-year postmarketing experience in the United States: STUDY





































Image Source: HEALTH

Effects of Ampyra (dalfampridine) Extended-Release Tablets on 6-Minute Walk Distance in Patients With MS: A Post Hoc Analysis of a Double-Blind, Placebo-Controlled Trial: STUDY































Image Source: ALEXXBACIU